Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$2.05
-0.04 (-1.91%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.01
▼
$2.13
50-Day Range
$0.55
▼
$2.25
52-Week Range
$0.51
▼
$2.43
Volume
272,452 shs
Average Volume
749,719 shs
Market Capitalization
$107.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GlycoMimetics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
1.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.57mentions of GlycoMimetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$143,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.91) to ($0.65) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

740th out of 1,044 stocks

Pharmaceutical Preparations Industry

350th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
GLYC stock logo

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

November 26, 2022 | americanbankingnews.com
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com
November 23, 2022 | finance.yahoo.com
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
November 19, 2022 | americanbankingnews.com
GlycoMimetics (NASDAQ:GLYC) Receives New Coverage from Analysts at StockNews.com
November 18, 2022 | americanbankingnews.com
Edwin Rock Acquires 100,000 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) Stock
November 12, 2022 | finance.yahoo.com
GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)
November 10, 2022 | finance.yahoo.com
Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k
November 9, 2022 | finance.yahoo.com
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
November 8, 2022 | finance.yahoo.com
GlycoMimetics to Participate in Two Upcoming Investor Conferences
November 3, 2022 | finance.yahoo.com
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
November 2, 2022 | finance.yahoo.com
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
October 19, 2022 | globenewswire.com
Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports - GlobeNewswire
October 19, 2022 | benzinga.com
Venous Thromboembolism Pipeline Assessment – Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drug - Benzinga
October 13, 2022 | businesswire.com
Vaso-occlusive Crisis-associated with Sickle Cell Disease Drug Pipeline Report 2022 - ResearchAndMarkets.com - Business Wire
October 11, 2022 | businesswire.com
BIO Announces Appointment of Interim CEO - Business Wire
October 4, 2022 | finance.yahoo.com
GlycoMimetics (GLYC) Upgraded to Buy: Here's Why
September 21, 2022 | benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - bluebird bio (NASDAQ:BLUE), Apexigen (NASDAQ - Benzinga
September 16, 2022 | benzinga.com
Sickle Cell Disease Treatment Global Market to Reach $4 Billion by 2027 - Benzinga
September 14, 2022 | streetinsider.com
Form 425 Maxpro Capital Acquisiti Filed by: Apollomics Inc. - StreetInsider.com
September 9, 2022 | benzinga.com
Sickle Cell Disease Treatment Global Market Report 2022: Increase in the Number of Individuals Suffering - Benzinga
September 8, 2022 | nasdaq.com
GlycoMimetics Says Edwin Rock Joins As Chief Medical Officer - Nasdaq
September 7, 2022 | seekingalpha.com
GlycoMimetics has a new chief medical officer - Seeking Alpha
September 7, 2022 | benzinga.com
GlycoMimetics (GLYC) – GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Invest - Benzinga
September 7, 2022 | finance.yahoo.com
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022 | finance.yahoo.com
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
August 9, 2022 | finance.yahoo.com
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights - Yahoo Finance
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings
11/02/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLYC
CUSIP
N/A
CIK
1253689
Web
www.glycomimetics.com
Phone
(240) 243-1201
Fax
301-738-2137
Employees
52
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,430,000.00
Net Margins
N/A
Pretax Margin
-57,921.50%
Return on Equity
-85.00%
Return on Assets
-72.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.95
Quick Ratio
6.95

Sales & Book Value

Annual Sales
$1.16 million
Price / Sales
92.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.92 per share
Price / Book
2.23

Miscellaneous

Outstanding Shares
52,420,000
Free Float
48,230,000
Market Cap
$107.46 million
Optionable
Optionable
Beta
1.86

Key Executives

  • Mr. Harout Semerjian (Age 52)
    CEO, Pres & Director
    Comp: $481.96k
  • Mr. Brian M. Hahn (Age 48)
    Sr. VP & CFO
    Comp: $804.38k
  • Dr. John L. Magnani (Age 69)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $803.16k
  • Ms. Stephanie R. Irish CPA (Age 51)
    VP of Accounting
  • Mr. Christian Dinneen-Long
    VP, Corp. Counsel & Corp. Sec.
  • Mr. Armand Girard (Age 53)
    Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.
  • Mr. Bruce Johnson
    Sr. VP & Chief Commercial Officer
  • Dr. Edwin Rock M.D.
    Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.

How have GLYC shares performed in 2022?

GlycoMimetics' stock was trading at $1.44 on January 1st, 2022. Since then, GLYC stock has increased by 42.4% and is now trading at $2.05.
View the best growth stocks for 2022 here.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GLYC earnings forecast.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The biotechnology company earned $0.09 million during the quarter. During the same quarter last year, the company earned ($0.29) earnings per share.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.59%), Renaissance Technologies LLC (1.00%), Two Sigma Investments LP (0.44%) and Two Sigma Advisers LP (0.39%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani and Patricia S Andrews.
View institutional ownership trends.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $2.05.

How much money does GlycoMimetics make?

GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $107.46 million and generates $1.16 million in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 11/27/2022 by MarketBeat.com Staff